AGEN logo

Agenus (AGEN) Company Overview

Profile

Full Name:

Agenus Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 8, 2000

Indexes:

Not included

Description:

Agenus is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. They create therapies that help the immune system recognize and attack cancer cells, aiming to improve patient outcomes and advance cancer care through research and clinical trials.

Key Details

Price

$3.75

Annual Revenue

$156.31 M(+59.47% YoY)

Annual EPS

-$13.80(+11.54% YoY)

Annual ROE

153.28%

Beta

2.89

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 12, 2024

Analyst ratings

Recent major analysts updates

Jan 22, 25 HC Wainwright & Co.
Neutral
Dec 5, 24 HC Wainwright & Co.
Neutral
Nov 29, 24 HC Wainwright & Co.
Neutral
Nov 12, 24 HC Wainwright & Co.
Neutral
Aug 14, 24 B. Riley Securities
Buy
Jul 19, 24 Jefferies
Hold
Jul 18, 24 HC Wainwright & Co.
Neutral
Jun 28, 24 HC Wainwright & Co.
Buy
May 24, 24 HC Wainwright & Co.
Buy
May 7, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
AGEN
businesswire.comJanuary 22, 2025

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings. Data presented also highlight BOT/BAL'.

What Makes Agenus (AGEN) a New Buy Stock
What Makes Agenus (AGEN) a New Buy Stock
What Makes Agenus (AGEN) a New Buy Stock
AGEN
zacks.comJanuary 20, 2025

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
AGEN
businesswire.comDecember 18, 2024

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in San Francisco, California. The presentations will showcase BOT/BAL's activity across three distinct co.

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
AGEN
businesswire.comDecember 5, 2024

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the compan.

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
AGEN
businesswire.comNovember 27, 2024

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company's cash p.

Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of the December 16, 2024 - ACHC
Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of the December 16, 2024 - ACHC
Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of the December 16, 2024 - ACHC
AGEN
globenewswire.comNovember 22, 2024

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Healthcare To Contact Him Directly To Discuss Their Options

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
AGEN
zacks.comNovember 15, 2024

Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates
Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates
AGEN
zacks.comNovember 12, 2024

Agenus (AGEN) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $2.10. This compares to loss of $3.20 per share a year ago.

November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
AGEN
accesswire.comNovember 5, 2024

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110801&wire=1 or contact Joseph E. Levi, Esq.

Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
AGEN
accesswire.comNovember 5, 2024

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110719&wire=1 or contact Joseph E. Levi, Esq.

FAQ

  • What is the ticker symbol for Agenus?
  • Does Agenus pay dividends?
  • What sector is Agenus in?
  • What industry is Agenus in?
  • What country is Agenus based in?
  • When did Agenus go public?
  • Is Agenus in the S&P 500?
  • Is Agenus in the NASDAQ 100?
  • Is Agenus in the Dow Jones?
  • When was Agenus's last earnings report?
  • When does Agenus report earnings?
  • Should I buy Agenus stock now?

What is the ticker symbol for Agenus?

The ticker symbol for Agenus is NASDAQ:AGEN

Does Agenus pay dividends?

No, Agenus does not pay dividends

What sector is Agenus in?

Agenus is in the Healthcare sector

What industry is Agenus in?

Agenus is in the Biotechnology industry

What country is Agenus based in?

Agenus is headquartered in United States

When did Agenus go public?

Agenus's initial public offering (IPO) was on February 8, 2000

Is Agenus in the S&P 500?

No, Agenus is not included in the S&P 500 index

Is Agenus in the NASDAQ 100?

No, Agenus is not included in the NASDAQ 100 index

Is Agenus in the Dow Jones?

No, Agenus is not included in the Dow Jones index

When was Agenus's last earnings report?

Agenus's most recent earnings report was on Nov 12, 2024

When does Agenus report earnings?

The next expected earnings date for Agenus is Mar 14, 2025

Should I buy Agenus stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions